CAR-Ts have already changed the treatment landscape when it comes to blood cancers, but getting a cell therapy to market for solid tumors remains tantalizingly out of reach. Now, Inceptor Bio and cell engineering tech company Avectas are taking on the challenge.

Sangamo Therapeutics has presented updated preliminary data from its phase 1/2 Fabry disease clinical trial, revealing that recipients of its gene therapy had elevated levels of a key enzyme even after stopping taking the standard of care.

Illumina signed up for a new collaboration with AstraZeneca with the goal of aligning their artificial intelligence development efforts in a way that combines genomic analysis and drug discovery research.

PureTech Health says merger talks with Nektar Therapeutics have ended, not even a week after the conversations were first confirmed.

NMD Pharma has reported phase 1/2a data on its myasthenia gravis candidate, furthering its efforts to treat an aspect of the disease that it thinks therapies from AstraZeneca, argenx, Johnson & Johnson and UCB are unable to address.

Fitbit’s wearable health trackers can be used to monitor daily activity, sleep patterns, heart rate, blood oxygen levels, skin temperature and, as of last month, possible signs of atrial fibrillation—and, now, all of those round-the-clock measurements could help support those recovering from substance abuse.

At a surface level, the sound of someone’s voice can offer insight into their mood and stress levels. But many medtech developers are aiming to go even deeper, applying artificial intelligence to snippets of speech to pick up on potential signs of disease.

Fresh off the U.S. debut of Senseonics’ Eversense E3 continuous glucose monitor system, the system’s distributor Ascensia Diabetes Care has now completed its initial launch in Europe, too.

Like many autoimmune diseases, Type 1 diabetes stems from effector T cells gone rogue. The immune cells launch an attack on the insulin-producing beta islet cells in the pancreas, leaving patients without the ability to process glucose. As a result, patients require lifelong insulin treatment.

Thermo Fisher Scientific is introducing a new, high-powered microscope aimed specifically at speeding up drug discovery research, with automated features that can help gather images at near-atomic resolution.